Stephanie Sacharow
Clinical Genetics (M.D.) · Boston, MANPI 1134328982
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 85.8% of it on its own, with 2 other manufacturers making up the rest. Among clinical genetics (m.d.) clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $934.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$69K
- PTC Therapeutics, Inc.$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
Across 108 payments — averaging $20,175 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$1.4M
- PTC Therapeutics, Inc.$825K
What the payments were for
- Consulting fees$20,30725%
- Speaking & faculty fees$29,40037%
- Travel & lodging$23,83930%
- Food & beverage$2,5393%
- Education$4,3035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 69 | $68,981 |
| PTC Therapeutics, Inc. | 10 | $10,223 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $1,184 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,388 in reported general payments places this provider in the 95th percentile of 33 clinical genetics (m.d.) providers in Massachusetts.
See all clinical genetics (m.d.) providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PalynziqPegvaliase-Pqpz | 16 | $258,428 |
| Sapropterin Dihydrochloride | 26 | $104,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq | $68,981 | $258,42816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 clinical genetics (m.d.) providers in Massachusetts.
Other clinical genetics (m.d.) in Boston
- Gerald CoxBoston$475K
- Wendy ChungBoston$37K
- Anatalia LabilloyBoston$11K
- Amy KritzerBoston$10K
- Edward NeilanBoston$9K
- Jonathan PickerBoston$8K
- Ingrid HolmBoston$8K
- Huma RanaBoston$5K
- Olaf BodamerBoston$5K
- Brian SkotkoBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.